Immuneering Corporation – NASDAQ:IMRX
Founder-led company
Immuneering stock price today
$3.38
+1.04
+45.06%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 7 hours
Immuneering stock price monthly change
+87.90%
month
Immuneering stock price quarterly change
+87.90%
quarter
Immuneering stock price yearly change
-68.51%
year
Immuneering key metrics
Market Cap | 63.03M |
Enterprise value | 255.95M |
P/E | -6.07 |
EV/Sales | 807.54 |
EV/EBITDA | -5.25 |
Price/Sales | 1021.44 |
Price/Book | 2.94 |
PEG ratio | -0.27 |
EPS | -1.86 |
Revenue | N/A |
EBITDA | -13.97B |
Income | -54.17M |
Revenue Q/Q | N/A |
Revenue Y/Y | -100% |
Profit margin | -15937.29% |
Oper. margin | -16325.96% |
Gross margin | 50.11% |
EBIT margin | -16325.96% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeImmuneering stock price history
Immuneering stock forecast
Immuneering financial statements
| Jun 2023 | 94.41M | -12.18M | -12.91% |
|---|---|---|---|
| Sep 2023 | 0 | -12.59M | |
| Dec 2023 | -94.41M | -15.08M | 15.98% |
| Mar 2024 | 0 | -14.30M |
| Mar 2024 | 0 | -14.30M | |
|---|---|---|---|
| Sep 2025 | 0 | -14.48M | |
| Oct 2025 | 0 | -13.06M | |
| Dec 2025 | 0 | -14.09M |
Analysts Price target
Financials & Ratios estimates
| 2023-11-09 | -0.51 | -0.43 |
|---|---|---|
| 2024-03-01 | -0.48 | -0.52 |
| 2024-05-07 | -0.45 | -0.49 |
| Jun 2023 | 124895330 | 9.79M | 7.84% |
|---|---|---|---|
| Sep 2023 | 113880939 | 9.86M | 8.66% |
| Dec 2023 | 102584538 | 12.00M | 11.71% |
| Mar 2024 | 87982840 | 9.26M | 10.52% |
| Jun 2023 | -10.74M | 9.16M | 28.17M |
|---|---|---|---|
| Sep 2023 | -12.02M | -23.97M | 21.44K |
| Dec 2023 | -11.77M | 3.13M | 7.83K |
| Mar 2024 | -15.49M | 21.39M | 979.92K |
Immuneering alternative data
| Aug 2023 | 68 |
|---|---|
| Sep 2023 | 66 |
| Oct 2023 | 66 |
| Nov 2023 | 66 |
| Dec 2023 | 67 |
| Jan 2024 | 67 |
| Feb 2024 | 67 |
| Mar 2024 | 68 |
| Apr 2024 | 68 |
| May 2024 | 68 |
| Jun 2024 | 65 |
| Jul 2024 | 65 |
Immuneering other data
7.68%
-36.74%
of IMRX is owned by hedge funds
17
-15
2.02M
-9.69M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Mar 2024 | 197083 | 909091 |
| Apr 2024 | 0 | 400000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 100 | $3.07 | $307 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 300 | $3.07 | $920 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 100 | $3.05 | $305 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 600 | $3.03 | $1,818 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 10 | $3.01 | $30 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 10 | $2.98 | $30 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 280 | $2.97 | $832 | ||
Sale | CORMORANT ASSET MANAGEMENT, LP 10 percent owner | Class A Common Stock | 398,600 | $2.9 | $1,155,940 | ||
Purchase | SCHALL THOMAS J. director | Class A Common Stock | 2,900 | $2.55 | $7,386 | ||
Purchase | FEINBERG PETER director | Class A Common Stock | 25,000 | $2.55 | $63,725 |
| Quarter | Transcript |
|---|---|
| Q4 2022 6 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. (1982) Co-Founder, Pres, Chief Executive Officer & Director | $806,040 |
Dr. Brett M. Hall Ph.D. (1968) Chief Scientific Officer | $775,200 |
Dr. Scott Barrett M.D. (1963) Chief Medical Officer | $715,400 |
-
What's the price of Immuneering stock today?
One share of Immuneering stock can currently be purchased for approximately $3.38.
-
When is Immuneering's next earnings date?
Unfortunately, Immuneering's (IMRX) next earnings date is currently unknown.
-
Does Immuneering pay dividends?
No, Immuneering does not pay dividends.
-
How much money does Immuneering make?
Immuneering has a market capitalization of 63.03M. Immuneering made a loss 53.47M US dollars in net income (profit) last year or -$0.49 on an earnings per share basis.
-
What is Immuneering's stock symbol?
Immuneering Corporation is traded on the NASDAQ under the ticker symbol "IMRX".
-
What is Immuneering's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Immuneering?
Shares of Immuneering can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Immuneering's key executives?
Immuneering's management team includes the following people:
- Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D. Co-Founder, Pres, Chief Executive Officer & Director(age: 43, pay: $806,040)
- Dr. Brett M. Hall Ph.D. Chief Scientific Officer(age: 57, pay: $775,200)
- Dr. Scott Barrett M.D. Chief Medical Officer(age: 62, pay: $715,400)
-
Is Immuneering founder-led company?
Yes, Immuneering is a company led by its founder Dr. Benjamin J. Zeskind M.B.A., MBA, Ph.D..
-
How many employees does Immuneering have?
As Jul 2024, Immuneering employs 65 workers, which is 4% less then previous quarter.
-
When Immuneering went public?
Immuneering Corporation is publicly traded company for more then 4 years since IPO on 30 Jul 2021.
-
What is Immuneering's official website?
The official website for Immuneering is immuneering.com.
-
Where are Immuneering's headquarters?
Immuneering is headquartered at 245 Main Street, Cambridge, MA.
-
How can i contact Immuneering?
Immuneering's mailing address is 245 Main Street, Cambridge, MA and company can be reached via phone at +61 75008080.
Immuneering company profile:
Immuneering Corporation
immuneering.comExchange:
NASDAQ
Full time employees:
66
Industry:
Biotechnology
Sector:
Healthcare
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
245 Main Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001790340
ISIN: US45254E1073
CUSIP: 45254E107
